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The role of high-dose myeloablative
chemotherapy with haematopoietic stem
cell transplantation (HSCT) in children with
central nervous system (CNS) tumours:
protocol for a systematic review and
meta-analysis
Caroline Main1* , Jayne S. Wilson1, Simon P. Stevens1, Aimee E. Houlton1, Martin English2, Pamela R. Kearns1,
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Abstract
Objectives: The objective of the study is to conduct a systematic review to compare the effects of high-dose
chemotherapy (HDCT) with autologous haematopoietic stem cell transplantation (HSCT) versus standard-dose
chemotherapy (SDCT) in children with malignant central nervous system (CNS) tumours.
Methods: Standard systematic review methods aimed at minimising bias will be employed for study identification,
selection and data extraction. Ten electronic databases will be searched, along with citation searching and
reference checking. Studies assessing the effects of HDCT with HSCT in children with CNS tumours will be included.
The outcomes are survival (overall, progression-free, event-free, disease-free), response rates, short- and long-term
adverse events and health-related quality of life (HRQoL). Two reviewers will independently screen and select
randomised and non-randomised controlled trials and controlled and uncontrolled observational studies for
inclusion. Quality assessment will be tailored to the different study designs. Where possible data will be
summarised using combined estimates of effect for the hazard ratio for survival outcomes and the risk ratio
for response rates. A fixed effect model will be used; sub-group analyses and meta-regression will be used to
explore potential sources of heterogeneity between studies.
Discussion: Given the poor prognosis of malignant brain tumours in children in terms of survival and quality
of life, this review will help guide clinical practice by summarising the current evidence on the use of high-dose
myeloblative chemotherapy with stem cell support in children with CNS tumours.
Keywords: Children, Central nervous system tumours, High-dose chemotherapy, Haematopoietic stem cell
transplantation, Systematic review
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Background
Tumours of the central nervous system (CNS) represent
a diverse group of neoplasms that account for approxi-
mately 25 % of all childhood cancers. They are the lead-
ing cause of cancer-related death in childhood and
severe morbidity in survivors. High-grade gliomas
(HGG) [glioblastoma multiforme (GBM) and anaplastic
astrocytomas (AA)], diffuse intrinsic pontine gliomas
(DIPG), primitive neuroectodermal tumours (PNETs,
including medulloblastoma) and ependymoma constitute
the majority of these malignant tumour types. To date,
multimodal treatment involving surgery, radiotherapy and
chemotherapy has formed the main stay of treatment for
CNS tumours. However, the survival rate remains poor in
some high-risk histological tumour types and for patients
with residual, recurrent or disseminated disease. Thera-
peutic options in most of these patients are limited by pre-
vious chemotherapy and radiotherapy and the need to
limit re-irradiation in second-line treatment due to the
deleterious effects on the developing brain and spinal cord.
High-dose chemotherapy (HDCT) followed by haem-
atopoietic stem cell transplantation (HSCT) has been used
as frontline as well as salvage therapy in children with a
variety of CNS malignancies [1–3]. This strategy is based
on the principle of high-dose therapy facilitating better
penetration of the blood-brain barrier (BBB) and an
increase in the dose-response curve to chemotherapeutic
compounds. Clinically, however, severe myelosuppression
limits dose escalation unless the haematopoietic system
can be rescued shortly after infusion. The use of HDCT
followed by HSCT has proven to be feasible and a number
of single arm phase II trials have assessed the effects of
HDCT with HSCT in different groups of children with
CNS tumours. These have included infants [4, 5] and
children with newly diagnosed [6] or relapsed medullo-
blastoma [7, 8], HGG [9–12] and relapsed or progressive
ependymoma [13]. The totality of the evidence related to
using HDCT with HSCT in children with CNS tumours
has however not been systematically assessed. This review
therefore aims to assess the effects of HDCT with HSCT
versus SDCT in children with malignant CNS tumours.
Methods
Standard systematic review methodology aimed at minimis-
ing bias will be employed, and reporting will follow the Pre-
ferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines [14]. The protocol for this
review is registered with PROSPERO (CRD42015020402).
Available from http://www.crd.york.ac.uk/prospero/display_
record.asp?ID=CRD42015020402).
Data sources and searches
This review forms part of a wider work programme of
systematic reviews which aim to assess the effects of
different interventions for the treatment of CNS tumours
in children, adolescents and young adults. Searches have
therefore been conducted for studies examining the effects
of surgery, radiotherapy, chemotherapy, immunotherapy,
hormone therapy, biological therapies and imaging used
alone or as part of a multi-modality treatment regimen for
all types of paediatric brain tumours. No study design
filters have been applied to the searches. Specific details of
the searches conducted are detailed below.
Bibliographic databases: A comprehensive, broad
search strategy was developed using a combination of
medical subject headings (MeSH) and free text terms.
The searches were limited by date from 1985 to
November week 1, 2014. No language or publication
status restrictions were applied, and ongoing studies
were included.
The searches for published studies were undertaken
using the following databases: MEDLINE (OvidSP);
MEDLINE In-Process Citations and Daily Update
(OvidSP); EMBASE (OvidSP); Cochrane Database of
Systematic Reviews (CDSR) (Wiley); Cochrane Central
Register of Controlled Trials (CENTRAL) (Wiley);
CINAHL Plus (EBSCO); Database of reviews of
effects [DARE (Centre for Reviews and Dissemination
(CRD) website)] and Health Technology Assessment
(HTA) (CRD website). The search strategy used for
the MEDLINE search is reported in Appendix 1.
Grey literature, completed and on-going studies
were identified by searches of NIH Clinical Trials
(http://www.clinicaltrials.gov/); Current Controlled
Trials (http://www.controlled-trials.com/) and WHO
International Clinical Trials Registry Platform (ICTRP)
(http://www.who.int/ictrp/en/).
Other sources: Experts in the field, from both the
Project Advisory and Patient and Public Involvement
(PPI) Groups were contacted with a list of identified
studies to find out whether they had knowledge of any
further studies that had not been retrieved by the elec-
tronic searches. Reference lists of all studies included
in the present review will be checked and citation
searching undertaken in order to identify any further
studies not retrieved by the electronic searches.
All identified references were downloaded into
Endnote X7 software for further initial assessment
and handling. As a preliminary first stage to the
broader set of reviews, inclusion screening on the
basis of the population and broader set of applicable
interventions was undertaken, with all included stud-
ies being ‘mapped’ by study design. Where flexibility
is needed throughout the work programme for refer-
ence management and handling, Endnote software
will be linked to bespoke Access databases in order
facilitate sorting and manipulation of data items
within indexed fields and abstracts.
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Inclusion/exclusion criteria
Population
Infants, children and young adults (up to age 25 years)
with diagnoses of any type of malignant CNS tumour.
These include but are not limited to high- and low-grade
gliomas (HGG and LGG), diffuse intrinsic pontine glioma
(DIPG), medulloblastoma, ependymoma, germ cell tu-
mours, atypical teratoid rhabdoid tumour (AT/RT), primi-
tive neuroectodermal tumours and pineoblastoma. Studies
that include both children and adults within the relevant
populations will be included provided results are reported
separately for children (defined as up to the age of 25).
Likewise, studies conducted in children with different
tumour types (e.g. solid tumours) will also be included
provided results are reported separately for CNS tumours.
Interventions
HDCT with HSCT. High-dose methotrexate will be ex-
cluded as the term high-dose is used in the context of
needing supportive care with folinic acid rescue as op-
posed to conventional standard dose methotrexate.
Comparator (for controlled studies): Standard or dose
intensive chemotherapy.
Outcomes
Overall survival (OS), progression-free survival (PFS),
disease-free survival (DFS), event-free survival (EFS),
response rates, short- and long-term adverse events
and health-related quality of life (HRQoL). Response
status data prior to and after HDCT regimens need to
be reported where either multi-modal therapy regi-
mens are being assessed or studies include populations
with different types of tumours within the same study.
Studies which do not report both baseline and post-
HDCT response data will be excluded.
Study designs
Randomised controlled trials (RCTs), non-randomised
comparative studies, single arm phase II trials, cohort
studies, case-control studies and case series (both pro-
spective and retrospective) will be included provided
that ten or more participants have been included in
studies that have assessed single tumour types and fif-
teen or more participants have been included in studies
that have assessed ‘mixed’ CNS tumour types within the
same study. Cross-sectional studies and multiple and
single case reports will be excluded.
Study selection
Study selection will be undertaken in two stages by two
reviewers working independently. Titles and abstracts
will be screened for inclusion/exclusion. Studies marked
for inclusion by either reviewer will then undergo full in-
dependent text assessment. Any discrepancies will be
resolved by recourse to the abstracts or full texts or
through consensus with a third reviewer. A PRISMA
flow chart illustrating the study selection process will be
documented [14].
Data extraction
Data will be recorded on a standard data extraction form
and entered onto a bespoke computer database developed
in either Access or Excel. The data will be extracted by one
reviewer and checked by a second for accuracy. Any dis-
crepancies will be resolved by recourse to the paper. Data
from studies with multiple publications will be extracted
and reported as a single study. Data will be extracted on
general [study name, study group (if applicable), publica-
tion date(s), principal investigator/authors]; eligibility and
study participants [e.g. tumour type and location; grade;
age, prior treatment history]; intervention and comparator
(if applicable); intervention(s) [drugs, doses, number of
cycles, administration, concomitant therapy], methods of
HSCT [including donor source and cell type(s)], study
design (e.g. RCT, non-randomised comparative study,
single-arm phase II trial, prospective or retrospective
case series], length of follow-up and timing of outcome
assessments; outcome measures (protocol specified—if
available—and reported); side effects/toxicity, long-term
adverse events and neurological outcomes; analysis
methods [intention to treat (ITT) or per protocol] and
author's conclusions. Outcomes for RCTs and observa-
tional studies will be recorded separately.
Assessment of risk of bias in studies
The quality of RCTs will be assessed using the eight criteria
in the Cochrane Collaboration’s tool for assessing risk of
bias, which covers random sequence generation and allo-
cation concealment (selection bias); blinding [(participants,
personnel and outcome assessors), performance and verifi-
cation bias]; completeness of outcome data (attrition bias);
selective outcome reporting (reporting bias) and other
sources of bias [15]. These criteria will be adapted for use
with non-randomised comparative studies, with an assess-
ment of baseline balance between groups being instigated
instead of an assessment of the method of random
sequence generation. For non-comparative studies, the six-
point checklist developed by CRD, York for the assessment
of observational studies will be utilised (https://
www.york.ac.uk/crd/guidance/) [16]. This checklist asks
whether the sample is representative of the usual clin-
ical population to whom the results will be extrapolated,
whether the inclusion criteria are explicit and individ-
uals entered the study at similar points in their disease
progression (selection bias), whether follow-up was long
enough for important outcomes to occur and whether
outcomes were assessed using objective criteria or
assessed blinded (detection bias). If a sub-series has
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been undertaken, it also asks whether there was a suffi-
cient description of the distribution of prognostic factors.
As well as the risk of bias tool and CRD checklist, for all
studies, there will be an assessment of the adequacy of the
sample size, the use of concomitant treatments, treatment
compliance, the use of objective outcomes and the timing
of outcome assessments, the appropriateness of the statis-
tical analysis and whether the author’s conclusions are
justified and consistent with the results presented. Exter-
nal validity will also be assessed according to the ability of
the reader to consider the applicability of the findings to a
patient group in practice.
All assessment will be at the overall study level, not at
the level of the individual outcomes. In addition to the
methodological criteria listed above, the GRADE frame-
work may be used to consider inconsistency between
studies, precision of results, likelihood of publication
bias and applicability of results to population(s) of inter-
est [17]. Quality assessment will be undertaken by one
reviewer independently and checked for accuracy by a
second. Any disagreements will be resolved by recourse
to the study paper(s), and a third reviewer will be con-
sulted where necessary.
Data synthesis and analysis
Narrative synthesis
A narrative synthesis of study results will be presented
(including text, figures and tables), to provide adequate
interpretation of study findings. Studies will be grouped
by tumour type, study design, intervention, and treat-
ment line (induction, consolidation, salvage). The out-
comes considered include overall survival, PFS, DFS,
EFS, response rates, adverse events and HRQoL. There-
fore, outcomes will be expressed in terms of hazard
ratios [HR; (adjusted or unadjusted)] and risk ratios
(RR). All analyses will be conducted per outcome, in-
cluding all studies that have reported data for the
outcome.
RCTs
Where more than one RCT has addressed the same
question and they are considered to be clinically similar
(based on patient population and study treatments),
results will be combined in a standard pair-wise meta-
analysis using assumption free methods. All analyses
will be carried out on an ITT basis where possible,
using the HR or RR as appropriate. Heterogeneity of
treatment effect, if present, will be investigated using
the chi-squared test for heterogeneity and the I2
statistic [18]. Further sub-group analyses, to explore
differences between the trials in terms of patient base-
line characteristics such as tumour grade, prior treat-
ments (dose, number of cycles) will be undertaken as
necessary to investigate whether the treatment effect
differs between patient sub-groups.
If feasible and significant heterogeneity is identified, this
will be investigated using meta-regression. The following
pre-specified factors will be investigated: quality of the
primary studies; tumour type; prior treatment regimens
(RT versus no RT); induction/consolidation/salvage ther-
apy; dose and number of treatment cycles. All analyses will
be conducted using RevMan (version 5.1) and STATA
(STATA™ for Windows, version 10.1, Stata Corp; College
Station, TX).
Assessment of small study effects
For each meta-analysis containing ten or more studies,
the likelihood of small study effects and publication bias,
namely the tendency for smaller studies to provide more
positive findings, will be investigated though the con-
struction of funnel plots and statistical tests for small
study effects (such as the Peters Test) [19].
Non-randomised comparisons
Differences in outcome between studies will be assessed
by formal statistical (e.g. chi-squared tests to compare
response rates) and if the data permit, appropriate tests
for time-to-event and continuous parameters. Graphical
displays will be constructed in order to allow informal
comparison of the results between studies. Differences
in baselines characteristics of the patients that might
explain any apparent differences in outcome will be
examined.
Where both RCTs and non-randomised studies have
assessed similar interventions within the same tumour
type, a comparison of the effect sizes between the two
different study designs will be conducted to evaluate any
differential treatment effects by study design.
Discussion
Although this methodology has been designed to be
comprehensive and to minimise bias, we anticipate
some limitations with this review. The evidence base
is likely to be highly heterogeneous with different
HDCT interventions evaluated as part of a multi-
modality treatment regimen. Furthermore, these will
be assessed in different patient populations as induc-
tion, consolidation or salvage therapy. Additionally,
the majority of the evidence will come from single-
arm phase II trials and small case series both of
which have a strong risk of bias. It is therefore likely
that any conclusions that can be drawn from the
review will be tentative with a lot of uncertainty.
However, given the paucity of the available evidence
in order to inform treatment decision making in
terms of the risk-benefit profile of different types of
HDCT in the treatment of children with CNS
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tumours, it is very important to undertake this
review.
To ensure that our findings have clinical impact on
patients, their parents and the physicians who care
for them, results will be disseminated broadly by
presenting at scientific conferences, publishing in
peer-reviewed journals, and through our established
Patient and Public Involvement (PPI) partners who
work for established high profile UK Brain Tumour
Charities and our Clinical Steering Group. For
completeness, a list of the individual’s and their affili-
ations involved in both of these groups is provided in
Appendix 2.
Appendix 1: Clinical Effectiveness Search Strategy
Medline (OvidSP): 1985—October Week 4 2014
1. Glioma/ or Brain Neoplasms/ or Meningioma/ or
Glioblastoma/ or Astrocytoma/
2. ((brain or brainstem or intracranial or posterior
fossa) adj3 (cancer* or carcinom* or tumour* or tumour*
or neoplasm*)).mp.
3. (Astrocytoma* or Brain Stem Glioma* or Medullo-
blastoma*or Primitive Neuroectodermal Tumo?r* or
ganglioneuroblastoma* or CNS neuroblastoma* or Epen-
dymoblastoma or Medulloepithelioma or Pineal Parenchy-
mal Tumour* or (Atypical Teratoid adj1 tumo?r*) or
Oligoastrocytoma or ((Pilocytic or Gemistocytic) adj1
astrocytoma*) or ependymoma or primitive neuroectal
tumo?r*).mp.
4. (((Diffuse fibrillary or Gemistocytic or Pilocytic
Pilomyxoid Protoplasmic Subependymal giant cell) adj1
astrocytoma*) or Oligoastrocytoma or Oligodendroglioma
or Oligoastrocytoma or Pleomorphic xanthoastrocytoma
or ((astrocytoma or oligoastrocytoma or oligodendrogli-
oma) adj1 astrocytoma*) or Glioblastoma or Gliomatosis
cerebri or Gliosarcoma or ((diffuse intrinsic pontine
glioma or low grade brain stem) adj1 glioma) or ((classic
or desmoplastic or nodular or large cell or nodularity)
adj1 medulloblastoma*) or Primitive Neuroectodermal
Tumo?r* or ((ganglioneuroblastoma or neuroblastoma)
adj 1central nervous system*) or Ependymoblastoma or
Pineoblastoma or pineal parenchymal tumo?r* or (cen-
tral nervous system adj1 atypical teratoid) or (central
nervous system adj 1 rhabdoid tumo?r*) or Germino-
mas or ((immature or mature or malignant transform-
ation) adj2 teratomas)).mp.
5. 1 or 2 or 3 or 4
6. exp Surgical Procedures, Operative/
7. surg*.mp.
8. debulk*.mp.
9. cytoreduc*.mp.
10. 6 or 7 or 8 or 9
11. (chemotherap* or antineoplastic agents or cytotoxic
or alkylating agents or nitrosoureas or antimetabolite* or
antitumor?r or ((antibod* or monoclonal) adj 3 Human*)
or plant alkyloid* or (hormone* adj 1 agent*) or anthracy-
cline* * or systemic therap*)).mp.
12. (Everolimus or Afinitor or Cetuximab or Erbitux
or Bevacizumab or Avastin or Cediranib or Recentin or
lomustine or CCNU or CeeNU or carmustine or BiCNU
or Carustine or Ethylnitrosourea or Streptozocin or So-
rafenib or Nexavar or tipifarnib or Zarnestra or Erlotinib
or Tarceva or Sorafenib or Nexavar or temsirolimus or
Torisel or Sunitinib or Sutent or irinotecan or Camptosar
or Campto or Vandetanib or Caprelsa or Cabozantinib
or Cometriq or XL184 or Axitinib or AG013736 or
Inlyta).mp.
13. 11 or 12
14. exp Immunotherapy/ae, cl, ct, mt, mo, nu, px, st
15. exp Genetic Therapy/ae, cl, ct, mt, mo, nu, ut
16. exp Imaging, Three-Dimensional/ or exp Whole
Body Imaging/ or exp Magnetic Resonance Imaging/
17. exp Tomography, Emission-Computed/ or exp
Four-Dimensional Computed Tomography/ or exp
Tomography/ or exp Tomography, Emission-Computed,
Single-Photon/ or exp Positron-Emission Tomography/
18. 16 or 17
19. (radiation therapy or radiotherap* or intensity
modulat* radiotherapy*or radiosurgery or radiation on-
cology or reduced boost volume radiotherap* or hyper
fractionat* stereotactic radiotherap*or adjuvant radio-
therap* or body radiotherap* stereotactic*or computer
assisted radiotherap*or computer assisted radiotherap*-
planning or conformal radiotherap* or dosage* radio-
therap* or dose fractionation* radiotherap* or high
energy radiotherap*or implant radiotherap*or intensity
or modulated radiotherap*or interstitial radiotherap*or-
image guided radiotherap*or stereotactic*guid* radio-
therap* or local therap*).mp.
20. 10 or 13 or 14 or 15 or 18 or 19
21. 5 and 20
22. (Response or overall survival or progression* free
survival or event* free survival or time to recurrence or
time to progression or disease* free interval* or endo-
crinopath* or ((growth or thyroid) adj 1 hormone adj 3
deficienc*) or ((glucocorticoid or gonadotropin) adj 3
deficienc*) or endocrine dysfuct* or (cardiac function*
adj 3 impair*) or ataxia or spastic paresis or visual dys-
function or epilepsy or hemiparesis or neurolog*
deficit*).mp.
23. 21 and 22
24. limit 23 to (year = ‘1985-Current’ and (‘newborn
infant (birth to 1 month)’ or ‘infant (1 to 23 months)’ or
‘preschool child (2 to 5 years)’ or ‘child (6 to 12 years)’
or ‘adolescent (13 to 18 years)’ or ‘young adult (19 to 24
years)’) and humans)
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Appendix 2
Abbreviations
AA: anaplastic astrocytomas—a rare grade III tumour that develops from the
neuroepithelial tissue; AT/RT: atypical teratoid rhabdoid tumour—an
embryonal tumour that can occur anywhere in the central nervous system;
BBB: blood-brain barrier—a highly selective permeable barrier that separates
the circulating blood from the brain extracellular fluid in the central nervous
system; CNS: central nervous system—the part of the nervous system
consisting of the brain and the spinal cord; DIPG: diffuse intrinsic pontine
gliomas—heterogeneous group of tumours occurring in the brainstem and
cervicomedullary junction that are typically anaplastic astrocytomas or
glioblastoma multiforme; GBM: glioblastoma multiforme—also known as
glioblastoma or grade IV astrocytoma it it involves the glial cells and develops
from the neuroepithelial tissues; HDCT: high-dose chemotherapy—an intensive
drug treatment to kill cancer cells, but that also destroys the bone marrow and
can cause other severe side effects. High-dose chemotherapy is usually
followed by bone marrow or stem cell transplantation to rebuild the bone
marrow; HGG: high-grade glioma—high-grade gliomas encompass the WHO
grade III gliomas (anaplastic astrocytoma) and grade IV gliomas (glioblastome
multiforme); HSCT: haematopoietic stem cell transplantation—the intravenous
infusion of haematopoietic stem cells usually derived from bone marrow,
peripheral blood or umbilical cord blood to re-establish haematopoietic
function in patients whose bone marrow or immune system is damaged or
defective; PNETs: primitive neuroectodermal tumours—a malignant neural crest
tumour; SDCT: standard dose chemotherapy—chemotherapy delivered within
standard dosing schedules without the use of haematopoietic stem cell
transplantation.
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